CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Josh Moon has been appointed Chief Operating Officer (COO) at Creative Testing Solutions (CTS), effe...
This is the first update to the original CTS communication distributed on July 6th. As previously co...
We are very excited to launch our new website! Please take a few moments to click around and explore...
We received an updated WNV package insert; please note the manufacturer and license number has been ...
As winter weather continues to move through parts of the US, we would like to remind you it may be n...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...